The company, which raised $460 million in an IPO in July, has developed a pipeline of selective agents, two of which have advanced to Phase I clinical trials.
The company will provide proprietary algorithms for analyzing omics and imaging data to define predictors of drug response and identify new biomarkers.
With the help of a companion diagnostic, the firm plans to file a new drug application with the FDA for the previously abandoned TKI in the second half of 2020.
Using corrected TMB and other variables allowed Johns Hopkins researchers to more accurately predict response to immune checkpoint blockade in lung cancer.
The group published results showing its method can faithfully recapitulate genome-wide measures of DNA repair deficiency using much smaller sequencing panels.
The St. Louis-based firm will offer a sequencing service to help researchers separate target signals from errors made during next-generation sequencing.
